You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The collaboration includes setting up a new testing laboratory that will investigate the use of alternative chemical reagents for test kits.
Avacta said it is aiming to complete development of Affimer reagents for the COVID-19 test by the end of May.
The multiplexed PCR-based test will use Aegea's technology to measure the virus from nasal or other swabs, even in asymptomatic patients.
Both the Israeli and Palestinian authorities have granted approval for the lab to perform 3,000 COVID-19 tests per day for Gaza residents.
The test, developed by the firms in six weeks, is part of a viral respiratory panel and runs on Bosch's point-of-care Vivalytic system.
Under the agreement, the companies will combine Oxgene's Adenoviral Protein Machine technology with Native Antigen Company's antigens.
The firms are developing a testing system that involves drawing fingertip blood and doing routine testing in Babson's CLIA-certified laboratory.
SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.
The molecular assay is expected to require a pharyngeal throat swab to deliver diagnostic results on a paper strip in under 30 minutes.
The firm has launched the AWS Diagnostic Development Initiative to accelerate diagnostic research and development for the coronavirus.
